Biomarker detection in circulating cells

• US 7,537,938 B2
• Filed: 01/26/2004
• Issued: 05/26/2009
• Est. Priority Date: 04/28/2000
• Status: Expired due to Fees

• Current Assignee: Virologic, Inc. (Laboratory Corporation Of America Holdings)
• Original Assignee: Monogram Biosciences, Inc. (Laboratory Corporation Of America Holdings)
• Inventors: Klopack, Thomas, Singh, Sharat, Kirakossian, Hrair
• Primary Examiner(s): Shibuya; Mark L
• Assistant Examiner(s): Do; Pensee T
• Application Number:
  US10/765,773
• Publication Number:
  US 20040157271A1
• Time in Patent Office: 1,947 Days
• Field of Search: 436/518, 436/526, 436/538, 436/540, 435/6, 435/7.1, 435/7.2, 435/7.7, 435/7.95, 435/7.72
• US Class Current: 436/526
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/54326 Magnetic particles
• CPC Class Codes: G01N 33/566 using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/6845 Methods of identifying protein-protein interactions in protein mixtures

Abstract

A method is provided for detecting biomarkers in rare circulating cells by forming an enriched population of cells immunomagnetically followed by biomarker detection using binding compounds having releasable molecular tags. Preferably, biomarkers comprising one or more protein-protein complexes are detected in circulating cancer cells metastasized from a solid tumor. In the presence of biomarkers, the molecular tags of the binding compounds are released and separated from the assay mixture for detection and/or quantification.

Claims

1. A method of detecting one or more protein-protein complexes of a rare cell type in a sample containing a mixed population of cells such that each protein-protein complex has a first protein and a second protein, the method comprising:

immunomagnetically isolating from the sample a subpopulation of cells containing the rare cell type with one or more antibody compositions, wherein each antibody composition is specific for a cell surface antigen of the rare cell type and wherein each antibody composition is attached to a magnetic particle;

combining with the subpopulation of cells

(a) one or more different first binding compounds specific for each first protein of each of the one or more protein-protein complexes of the rare cell type, wherein each first binding compound has one or more molecular tags attached thereto via a cleavable linkage, the one or more molecular tags of each different binding compound having a distinct separation characteristic so that the one or more molecular tags of each different binding compound form distinct peaks in a separation profile upon separation; and

(b) one or more different second binding compounds specific for each second protein of each of the one or more protein-protein complexes of the rare cell type, wherein each second binding compound is conjugated to a cleaving-inducing moiety having an effective proximity;

wherein each of the first binding compounds specifically binds to each first protein and each of the second binding compounds specifically binds to each second protein, and wherein the one or more molecular tags of each first binding compound are released; and

separating and identifying the released by the cleaving-inducing moiety when in effective proximity to said one or more molecular tags molecular tags to detect the one or more protein-protein complexes in the sample.

2. The method of claim 1 wherein said protein-protein complex is a receptor dimer.

3. The method of claim 2 wherein said predetermined separation characteristic is electrophoretic mobility.

4. The method of claim 2 wherein said receptor dimer comprises one or more ErbB receptors.

5. The method of claim 4 wherein said protein-protein complex is selected from the group consisting or Her1//Shc, Her2//Shc, Her3//Shc, Her3/PI3K, and IGF-1R//PI3K.

6. The method of claim 1, wherein the rare cell type is a cancer cell.

7. The method of claim 1, wherein the rare cell type is a fetal cell.

8. The method of claim 1, wherein the sample is a patient sample.

9. The method of claim 1, wherein the sample is a biological sample.

10. The method of claim 9, wherein the biological sample is a culture, blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum, semen, needle aspirate sample.

11. The method of claim 10, wherein the biological sample is a blood sample.